Compare Nuwellis Inc (NUWE) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Recursion Pharmaceuticals Inc — how do they compare? Nuwellis Inc trades at $2.95 (market cap $1.09M), while Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 1403.7× Nuwellis Inc's market cap. Which is the better fit depends on your goals.
| NUWE | RXRX | |
|---|---|---|
Market Cap | $1.09M | $1.53B |
Sector | Technology | Health |
52-Week High | $527.46 | $6.79 |
52-Week Low | $2.80 | $2.84 |
Enterprise Value | -$722.58K | $946.50M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
